NDC 0169-4060
Victoza
Liraglutide
Victoza is a Subcutaneous Injection in the Human Prescription Drug category. It is labeled and distributed by Novo Nordisk. The primary component is Liraglutide.
| Product ID | 0169-4060_15c86a89-8747-40bc-8339-287e8785bba9 |
| NDC | 0169-4060 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Victoza |
| Generic Name | Liraglutide |
| Dosage Form | Injection |
| Route of Administration | SUBCUTANEOUS |
| Marketing Start Date | 2010-01-25 |
| Marketing Category | NDA / NDA |
| Application Number | NDA022341 |
| Labeler Name | Novo Nordisk |
| Substance Name | LIRAGLUTIDE |
| Active Ingredient Strength | 6 mg/mL |
| Pharm Classes | GLP-1 Receptor Agonist [EPC],Glucagon-Like Peptide 1 [CS],Glucagon-like Peptide-1 (GLP-1) Agonists [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |
Packaging
NDC 0169-4060-12
2 SYRINGE, PLASTIC in 1 CARTON (0169-4060-12) > 3 mL in 1 SYRINGE, PLASTIC
| Marketing Start Date | 2010-01-25 |
| NDC Exclude Flag | N |
| Sample Package? | N |
NDC SPL Data Element Entries
NDC 0169-4060-12 [00169406012]
Victoza INJECTION
| Marketing Category | NDA |
| Application Number | NDA022341 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2010-01-25 |
NDC 0169-4060-90 [00169406090]
Victoza INJECTION
| Marketing Category | NDA |
| Application Number | NDA022341 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2010-01-25 |
NDC 0169-4060-97 [00169406097]
Victoza INJECTION
| Marketing Category | NDA |
| Application Number | NDA022341 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2010-10-15 |
| Marketing End Date | 2015-03-31 |
NDC 0169-4060-99 [00169406099]
Victoza INJECTION
| Marketing Category | NDA |
| Application Number | NDA022341 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2015-02-13 |
NDC 0169-4060-98 [00169406098]
Victoza INJECTION
| Marketing Category | NDA |
| Application Number | NDA022341 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2013-04-15 |
| Marketing End Date | 2016-11-30 |
NDC 0169-4060-13 [00169406013]
Victoza INJECTION
| Marketing Category | NDA |
| Application Number | NDA022341 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2010-01-25 |
Drug Details
Active Ingredients
| Ingredient | Strength |
|---|---|
| LIRAGLUTIDE | 6 mg/mL |
OpenFDA Data
| SPL SET ID: | 5a9ef4ea-c76a-4d34-a604-27c5b505f5a4 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
Pharmacological Class
- GLP-1 Receptor Agonist [EPC]
- Glucagon-Like Peptide 1 [CS]
- Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
NDC Crossover Matching brand name "Victoza" or generic name "Liraglutide"
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0169-4060 | Victoza | liraglutide |
| 50090-2853 | Victoza | liraglutide |
| 50090-4503 | Victoza | liraglutide |
| 0169-2800 | Saxenda | liraglutide |
| 50090-4257 | Saxenda | liraglutide |
Trademark Results [Victoza]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 VICTOZA 76477425 2806406 Live/Registered |
Novo Nordisk A/S 2002-12-20 |
© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.